Cancer Risk in NAFLD Higher With Early Disease Onset
The risk for cancer in patients with nonalcoholic fatty liver disease (NAFLD) was highest among those with early-onset disease and declined at later ages of diagnosis, a matched cohort study found. Examining more than 60,000 participants from a prospective Chinese dataset revealed that the increased risk of malignancy with NAFLD was highest among patients diagnosed […]
NAFLD and T2DM Bodes Higher Risk of Liver Decompensation, Cancer
Patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes may be at significantly higher risk of hepatic decompensation and liver cancer, researchers reported. In a meta-analysis of six studies that included 1,737 patients with NAFLD followed for approximately 3 years, those with diabetes had twice the risk for developing hepatic decompensation (HR 2.15, […]
‘Game Changer’ in NASH: Resmetirom Hits Endpoints in Pivotal Study
VIENNA — The investigational agent resmetirom resolved liver biopsy findings in nonalcoholic steatohepatitis (NASH) more often than placebo, according to the phase III MAESTRO-NASH trial. While 10% of placebo patients achieved resolution of inflammation, ballooning, and disease activity, the rate was 26% among people treated with the 80-mg dose of resmetirom and 30% with the […]
Fatty liver disease endangers brain health
In a study examining the link between non-alcoholic fatty liver disease (NAFLD) and brain dysfunction, scientists at the Roger Williams Institute of Hepatology, affiliated to King’s College London and the University of Lausanne, found an accumulation of fat in the liver causes a decrease in oxygen to the brain and inflammation to brain tissue — […]
NAFLD Tied to Higher Risk of Heart Failure
Middle-age patients with non-alcoholic fatty liver disease (NAFLD) had a moderately higher risk of developing heart failure, an updated meta-analysis found. Pooled data on over 11 million participants showed NAFLD to be associated with a 50% greater risk of incident heart failure over a decade (pooled random-effects HR 1.50, 95% CI 1.34-1.67, P<0.0001), reported Giovanni […]
Nonalcoholic Fatty Liver Disease in Lean Patients Linked With CVD Risk
Lean patients with nonalcoholic fatty liver disease (NAFLD) were more likely to have cardiovascular disease (CVD) than those overweight or obese, a researcher reported. Among over 18,000 such patients, logistic regression analysis — adjusting for demographics and clinical risk factors — showed patients with overweight or obesity with NAFLD were associated with a significantly lower […]
Iron Load in NAFLD Tied to Higher Liver Cancer Risk
Patients with nonalcoholic fatty liver disease (NAFLD) had a significantly higher risk of developing hepatocellular carcinoma (HCC) based on elevated biomarker levels of serum iron or transferrin saturation, a researcher reported. In an analysis of over 18,000 NAFLD patients, elevated serum iron levels over 175 μg/dL were associated with a more than two-fold higher risk […]
A newly discovered genetic link to non-alcoholic inflammatory liver disease
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver unrelated to alcohol abuse or other liver diseases. It is often associated with obesity and diabetes and is considered a manifestation of metabolic syndrome. It progresses into non-alcoholic steatohepatitis (NASH) with the onset of inflammation, although it is currently unclear how this […]